Armoring multifunctional T cells for cancer therapy

Projektinformationen

ARMOR-T

ID Finanzhilfevereinbarung: 756017

DOI

10.3030/756017

Projekt abgeschlossen

EK-Unterschriftsdatum 20 September 2017

Startdatum 1 März 2018

Enddatum 29 Februar 2024

Finanziert unter

• EXCELLENT SCIENCE - European Research Council (ERC)

Gesamtkosten

€ 1 636 710,00

EU-Beitrag

€ 1 636 710,00

Koordiniert durch

LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN
Germany

Periodic Reporting for period 4 - ARMOR-T (Armoring multifunctional T cells for cancer therapy)

Berichtszeitraum: 2022-09-01 bis 2024-02-29

Zusammenfassung vom Kontext und den Gesamtzielen des Projekts

Cellular therapies are the therapeutic use of T cells which have become part of the standard of care in certain blood-borne cancers indications, related to a minority of cancer patients.. From basic studies, it is expected that this type of treatment should be applicable to much more frequent situations and diseases such as solid cancer types. In contrast, clinical studies so far failed to demonstrate activity in these diseases. A major reasons lays in a very different biology between solid and hematological cancers. These key differences have so far been overlooked in cell therapy development. ARMOR-T has taken up the challenge to solve these problems by means of engineering of cells. Such novel therapeutic pipeline has the potential to offer promising treatments to patients suffering from a wide variety of cancer types such as pancreatic, colon or breast cancer. ARMOR-T has a) established novel methods of engineering, b) selected promising engineering combinations and c) tested and characterized such novel strategies. ARMOR-T has layed the basis for further preclinical development and future clinical testing.

Arbeit, die ab Beginn des Projekts bis zum Ende des durch den Bericht erfassten Berichtszeitraums geleistet wurde, und die wichtigsten bis dahin erzielten Ergebnisse

ARMOR-T has set out to validate novel tumor targeting platforms utilizing specific immune cells, so called T cells (such as Karches et al., Clin Can Res 2019 and Stock, JITC 2022). ARMOR-T could also establish a novel technique of genetic modification of T cells to ameliorate tumor tissue recruitment and prove its efficacy in preclinical models (Lesch et al., Nat Biomed Eng 2021 and Cadilha et al., Science Adv. 2021). ARMOR-T has also pioneered a method for identifying novel tumor-associated target structures and design novel receptors against these (such as Gottschlich et al., Nat Biotech 2023 and Märkl et al., Nat Com 2024). These results have been broadly presented at scientific meetings (such as ESMO and ESMO IO) and the most promising candidates are now in further preclinical development towards therapy.

Fortschritte, die über den aktuellen Stand der Technik hinausgehen und voraussichtliche potenzielle Auswirkungen (einschließlich der bis dato erzielten sozioökonomischen Auswirkungen und weiter gefassten gesellschaftlichen Auswirkungen des Projekts)

Previous work has mainly focused on effectively targeting the cancer cell and has already led to the approval of gene engineered T cells for distinct indications. The particular biology of non-hematological cancer types has however been mostly disregarded. ARMOR-T has proposed to specifically address said differences through multiple engineering. Such approach has the potential to offer a unique therapeutic avenue for patients suffering from multiple cancer types. ARMOR-T has pioneered novel approaches involving cell engineering and will now progress to developping actual products for future clinical testing and application.

Lytic synapse formation between two T cells and one tumor cell